Cost-effectiveness analysis in the Spanish setting of the PEAK trial of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer-Reference-Cited by-同舟云学术

Cost-effectiveness analysis in the Spanish setting of the PEAK trial of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer

Published:2017-02-07 Issue:6 Volume:20 Page:574-584
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Rivera Fernando¹,Valladares Manuel²,Gea Salvador³,López-Martínez Noemí⁴

Affiliation:

1. Hospital Universitario Marqués de Valdecilla, Santander, Spain;

2. Hospital Universitario Virgen del Rocío, Sevilla, Spain;

3. Unidad de Farmacoeconomía e Investigación de Resultados en Salud, AMGEN, S.A., Barcelona, Spain;

4. Oblikue Consulting S.L., Barcelona, Spain

Funder

AMGEN

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2017.1285780

Reference57 articles.

1. Global cancer statistics, 2012

2. Sociedad Española de Oncología Médica (SEOM). Las cifras del cáncer en España 2014. Madrid: SEOM, 2014. www.seom.org/seomcms/images/stories/recursos/Las_cifras_del_cancer_2014.pdf. Accessed August 6, 2015

3. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

4. Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug Combination Therapy for RAS-related Colorectal Cancer;PROG BIOCHEM BIOPHYS;2023

2. Cost-Effectiveness of Lorlatinib for the Treatment of Adult Patients with Anaplastic Lymphoma Kinase Positive Advanced Non-Small Cell Lung Cancer in Spain;ClinicoEconomics and Outcomes Research;2023-09

3. Cost-effectiveness Analysis of Monoclonal Antibodies in the First-line Treatment of RAS Wild-type Metastatic Colorectal Cancer: A Systematic Review;Clinical Therapeutics;2023-01

4. Economic Evaluation of Monoclonal Antibodies in Metastatic Colorectal Cancer: A Systematic Review;Molecular Diagnosis & Therapy;2021-11

5. Cost-effectiveness indicator for colorectal cancer therapy;Pacific Medical Journal;2020-12-28